I was chuckling to myself at the irony. Dismal financials, yet one of the better calls in some time - no beach toys. How the next round of financing progresses will be a tell as to the view on the company's underlying value. I agree that large dilution with a plan and customers will be the toll of operations for mblx and will at least allow them to remain debt free - not that they could get a good bond rate anyways.
I've been in exas a number of years and if you want to see a turn around story check out their 5yr graph - trading at 0.29 on 2008. Hate tech. Love tech.
Your point about employees is well taken - despite the wreckage, not one peep outta Lowell about employee exodus. This to me speaks volumes. I've said it many times, this is a rock solid R&D operation. Tepha also seems to be busy establishing itself in the biomedical domain.
Here's from another PR and shows the desire to add fibers - a big deal folks.
The inspiration for the fermentation process of the Reinier de Graaf Hospital in Delft. That hospital already embraced in 2010 the concept of the company Pharmafilter. In Delft now grinds the shredder waste department for several years as a meal leftovers, bedpo's blood bags and tableware.
Crockery, bed linen and gowns ferment.
"Tonto" is the shredding of Pharmafilter baptized, Spanish for "a dwaas'. The granulated products go to be separated a central unit, where solids and water. The organic portions go to the digester, indigestible parts and conventional plastic comes in a sludge fraction and the aqueous fraction is treated in a membrane bioreactor, activated carbon and ozone after making short work of drug residues.
Rijnstate now wants to go a step further. "Using the list of bio-based materials from Wageningen UR we will try a much bigger part of our hospital to ferment," says Koster. The list includes not only the known disposable coffee cups but also all kinds of sputumbakjes, syringes, linens, hats, shoes and gowns.
Don't know if I believe but at this price, to me, there are good pot odds. Picked up a low risk # of shares and will see what happens with dilution - if it drops to 0.30, heck I got $900 laying around and MIGHT pick up 3K shares. They have always had good tech and R&D, and it was at least nice to hear that Ollie P. confirmed my thoughts on their crop research; read the patent people it is not trivial stuff. Interesting that we heard zilch on Pharmafilter. Best to all
For obtuse reasons only known to the failing Yahoo my last post on this was pulled. Go to Google News and search Pharmafilter - Rijnstate hospital in Arnhem is doing feasibility analysis to install 51 shredders. Looking into gowns, socks and fiber related applications. Let see if this post lasts.
Tis their only hope at this point. PhF is locking down contracts and appears to have a well regarded system. The PRs indicate a desire to move as many single use plastic items into the PhF waste stream as possible. Fingers crossed but staying realistic.
You know, I thought the same. All the FUD about blood tests and these guys actually have reasonable initial blood test data - not that it will work for pre-cancerous lesions.
From the reading it almost seems that they just ran the plasma samples as part of proof of concept and that they'll move toward expansion of stool based applications for early detection.
Subesquently using these tissue biomarker panels ...on more than 300 normal and cancerous tissue samples, the researchers were able to accurately predict the type of cancer with an accuracy of 88%. Meanwhile testing the plasma biomarker panel on 42 independent plasma samples yielded an accuracy of 74% in distinguishing colorectal from pancreatic tumors.
"most of the error in that came from the sensitivity rather than specificity, meaning we missed a few of the cancers, probably due to sub-optimal sample conditions. We think probably with larger blood volumes that we collect on our own, we'll do better, as the samples we used for this were convenient; they were not collected according to our specifications...."
From a group of around 100 markers they used bioinformatics approaches to home in on a three marker panel for the unifersal detection of GI neoplasms with 95% accuracy; 2 markers to distinguish between upper and lower GI cancers and lower cancers with 94% accuracy. In addition they identified a 2 marker plasma based panel that was 78% accurate in assigning patients to cancer or control groups and 83% accurate in assigning cancer origin to colorectal or pancreatic sites.